https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-07-23 / Vaccine 2011 Sep;29(38):6454-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-07-23 / Vaccine 2011 Sep;29(38):6454-632011-07-23 00:00:002019-02-15 08:47:56Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-07-22 / Neuro-oncology 2011 Oct;13(10):1049-58
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-07-22 / Neuro-oncology 2011 Oct;13(10):1049-582011-07-22 00:00:002019-02-15 08:46:38Treatment of high-grade glioma in children and adolescents
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-07-20 / Br J Haematol 2011 Aug;154(4):448-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-07-20 / Br J Haematol 2011 Aug;154(4):448-562011-07-20 00:00:002011-07-20 00:00:00Serum selenium concentration at diagnosis and outcome in patients with haematological malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-07-19 / Clin. Cancer Res. 2011 Sep;17(17):5725-35
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-07-19 / Clin. Cancer Res. 2011 Sep;17(17):5725-352011-07-19 00:00:002019-02-15 08:49:18Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-07-01 / Immunotherapy 2011 Jul;3(7):805-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-07-01 / Immunotherapy 2011 Jul;3(7):805-72011-07-01 00:00:002019-02-15 08:52:17Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-28 / J Clin Neurosci 2011 Aug;18(8):1048-54
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-28 / J Clin Neurosci 2011 Aug;18(8):1048-542011-06-28 00:00:002019-02-15 08:46:40A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-28 / Cancer 2012 Jan;118(1):180-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-28 / Cancer 2012 Jan;118(1):180-72011-06-28 00:00:002011-06-28 00:00:00Reirradiation and hyperthermia for radiation-associated sarcoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-23 / Radiother Oncol 2011 Oct;101(1):109-15
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-23 / Radiother Oncol 2011 Oct;101(1):109-152011-06-23 00:00:002019-02-15 09:17:20Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-23 / Clin. Cancer Res. 2011 Aug;17(16):5233-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-23 / Clin. Cancer Res. 2011 Aug;17(16):5233-82011-06-23 00:00:002019-02-15 08:52:51Prostate cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-06-17 / J Clin Oncol 29: 2011 (suppl; abstr e13029)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-06-17 / J Clin Oncol 29: 2011 (suppl; abstr e13029)2011-06-17 11:41:282019-07-17 11:42:05Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations.
